Has the Abbott Laboratories Sell-Off Finally Created an Entry Point?

By Trey Thoelcke Published Apr 20, 7:05AM EDT

Quick Read

Abbott Laboratories (ABT) stock has been punished hard in 2026, and the question is whether that punishment has overshot the fundamentals.
Abbott Labs is a quality franchise at a discounted price, but some investors may want to wait for two key developments to be resolved.

Follow 24/7 Wall St. on Google

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Has the Abbott Laboratories Sell-Off Finally Created an Entry Point? — © Sundry Photography / iStock Editorial via Getty Images

Whether Abbott Laboratories (NYSE: ABT | ABT Price Prediction) stock is at a good entry point depends on your investment horizon and tolerance for near-term uncertainty. The stock has been punished hard in 2026, and the question is whether that punishment has overshot the fundamentals.

Abbott Labs is a diversified healthcare giant spanning medical devices, diagnostics, nutrition, and established pharmaceuticals. Its $168 billion market cap reflects decades of compounding, but the stock has unwound gains over the past year. A $21 billion acquisition of Exact Sciences, completed in March, added cancer diagnostics brands Cologuard and Cancerguard while introducing integration costs and EPS dilution the market is still digesting.

The Bull Case: Quality at a Discount

Abbott delivered a clean beat in its most recent quarter. Net sales reached $11.164 billion, up 7.78% year-over-year, while adjusted diluted EPS came in at $1.15, extending a four-quarter streak of beating EPS estimates. Medical Devices led with $5.539 billion in revenue, up 13.2%, anchored by FreeStyle Libre CGM sales of $2.080 billion, up 7.5%.

The Exact Sciences deal positions Abbott as a leader in oncology diagnostics, a fast-growing market with significant underpenetration. CEO Robert Ford called it “another high-growth business to the Abbott portfolio, further strengthening our confidence in delivering accelerating growth as we move through the year.” Full-year guidance calls for comparable sales growth of 6.5% to 7.5% and adjusted EPS of $5.38 to $5.58. Abbott has also declared its 409th consecutive quarterly dividend of $0.63 per share, its 54th consecutive year of dividend increases, a track record few companies match.

The Bear Case: Litigation Risk and Dilution

The stock fell roughly 4.7% on the day of the Q1 earnings beat, even as the broader market rose. That reaction signals real concern. The Exact Sciences acquisition will dilute 2026 EPS by approximately $0.20 per share, and the nutrition segment posted a 6% revenue decline in Q1, with pediatric nutrition down 8.5%.

NEC baby formula litigation adds quantifiable risk. An Illinois jury awarded $70 million in damages to four families alleging Abbott’s Similac Special Care 24 formula caused necrotizing enterocolitis in premature infants. Abbott is appealing, but more cases are pending. Combined with operating income declining 20.32% year-over-year due to acquisition costs, the near-term earnings picture is cloudy.

The Hold Case: Uncertainty Outweighs Conviction

Abbott’s core businesses perform well, making a full sell conviction hard to justify. But litigation overhang, nutrition weakness, and integration costs create enough noise that adding to the position at current levels carries real risk. The stock trades well below its 200-day moving average of $122.79 and its 52-week high of $136.28, reflecting a significant decline from recent highs. Watch for litigation developments, nutrition volume recovery, and CGM reimbursement expansion before adding aggressively.

What the Numbers Say

Abbott trades at a forward P/E of 17x and a trailing P/E of 27x. Consensus analyst target is $120.00, and across 28 analysts, there are six Strong Buy ratings, 16 Buy ratings, six Hold ratings, and no Sell ratings. The stock is down 22.7% year-to-date, a stark contrast to the S&P 500, which is up 4.1% over the same period. The gap between current price and consensus target reflects meaningful upside if execution improves.

The Verdict

The bull case is real. The device portfolio grows at double-digit rates, Exact Sciences adds a high-growth oncology franchise, and the dividend record is unmatched in healthcare. Income investors with a multi-year horizon have a credible argument that this price represents a genuine entry point into a Dividend Aristocrat trading at a meaningful discount to analyst targets.

The bear case is also real. NEC litigation creates open-ended liability impossible to model precisely. Nutrition is shrinking. Integration costs suppress reported earnings. The market has twice punished Abbott on earnings beats, suggesting investors focus on risks the adjusted EPS line does not fully capture.

Wait for two developments: meaningful litigation clarity on NEC cases and evidence that nutrition volume is recovering rather than stabilizing. Both should be visible within two quarters. Investors needing near-term stability should hold or stay on the sidelines. Those with longer horizons and comfort with uncertainty may find the current price attractive, but size conservatively until litigation clears. Abbott is a quality franchise at a discounted price, but the discount reflects real risks that remain unresolved right now.

About the Author Trey Thoelcke →

Trey has been an editor and author at 24/7 Wall St. for more than a decade, where he has published thousands of articles analyzing corporate earnings, dividend stocks, short interest, insider buying, private equity, and market trends. His comprehensive coverage spans the full spectrum of financial markets, from blue-chip stalwarts to emerging growth companies.

Beyond 24/7 Wall St., Trey has created and edited financial content for Benzinga and AOL's BloggingStocks, contributing additional hundreds of articles to the investment community. He previously oversaw the 24/7 Climate Insights site, managing editorial operations and content strategy, and currently oversees and creates content for My Investing News.

Trey's editorial expertise extends across multiple publishing environments. He served as production editor at Dearborn Financial Publishing and development editor at Kaplan, where he helped shape financial education materials. Earlier in his career, he worked as a writer-producer at SVE. His freelance editing portfolio includes work for prestigious clients such as Sage Publications, Rand McNally, the Institute for Supply Management, the American Library Association, Eggplant Literary Productions, and Spiegel.

Outside of financial journalism, Trey writes fiction and has been an active member of the writing community for years, overseeing a long-running critique group and moderating workshop sessions at regional conventions. He lives with his family in an old house in the Midwest.